Responses
Clinical/translational cancer immunotherapy
Original research
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.